Comorbid patient with chronic heart failure: possibilities of sacubitril/valsartan


DOI: https://dx.doi.org/10.18565/therapy.2021.6.146-155

Larina V.N.

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow
Abstract. Heart failure provokes the progression of many diseases, and in recent years its contribution to the global «burden» of diseases associated with a poor prognosis has been confirmed, which requires the search for effective, from the point of view of evidence-based medicine, drug therapy. In 2015, the FDA approved for use a combination drug containing an antagonist of neprilisin and angiotensin II type 1 receptors – sacubitril/valsartan for the treatment of patients with chronic heart failure II–IV functional class and low left ventricular ejection fraction. This decision was based on the results of the PARADIGM-HF study, which confirmed the higher efficacy of sacubitril/valsartan in reducing mortality when compared with enalapril. Currently, a number of major studies are being carried out evaluating the effects of sacubitril / valsartan in patients with different heart failure phenotypes, which is reflected in this article. The advantages and disadvantages of this drug are discussed, as well as the priority group of patients with heart failure who are sensitive to the effects of sacubitril/valsartan.
Keywords: heart failure prognosis, heart failure phenotypes, neprilisin, sacubitril/valsartan, heart failure
Read entire article

Literature


  1. Benjamin E.J., Muntner P., Alonso A. et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019; 139: e56–e528. doi: 10.1161/CIR.000000000000065.

  2. Loehr L.R., Rosamond W.D., Chang P.P. et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008; 101(7): 1016–22. doi: 10.1016/j.amjcard.2007.11.061.

  3. Фомин И.В., Беленков Ю.Н., Мареев В.Ю. с соавт. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность. 2006; 3: 112–115. [Fomin I.V., Belenkov Yu.N., Mareev V.Yu. et al. The prevalence of chronic heart failure in the European part of the Russian Federation – data from EPOCHA-CHF study. Zhurnal Serdechnaya Nedostatochnost’ = Heart Failure Journal. 2006; 3: 112–115 (In Russ.)].

  4. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. с соавт. Истинная распространенность ХСН в Европейской части Российской Федерации (исследование ЭПОХА, госпитальный этап). Журнал Сердечная Недостаточность. 2011; 2: 63–68. [Belenkov Yu.N., Mareev V.Yu., Ageev F.T. et al. The true prevalence of CHF in the European part of the Russian Federation (EPOCHA study, hospital stage). Zhurnal Serdechnaya Nedostatochnost’ = Heart Failure Journal. 2011; 2: 63–68 (In Russ.)].

  5. Поляков Д.С., Фомин И.В., Вайсберг А.Р. ЭПОХА-Д-ХСН: гендерные различия в прогнозе жизни больных ХСН при острой декомпенсации сердечной недостаточности (часть 2). Кардиология. 2019; 4S: 33–43. [Polyakov D.S., Fomin I.V., Vaysberg A.R. EPOCHA-D-CHF: gender differences in the prognosis of patients with CHF after acute decompensation (part 2). Kardiologiya = Cardiology. 2019; 4S: 33–43 (In Russ.)]. doi: https://doi.org/10.18087/cardio.2654.

  6. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; 8: 7–13. [Fomin I.V. Chronic heart failure in the Russian Federation: what we know today and what we should do. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2016; 8: 7–13 (In Russ.)]. doi: https://dx.doi.org/10.15829/1560-4071-2016- 8-7-13.

  7. Barnett K., Mercer S.W., Norbury M. et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012; 380(9836): 37–43. doi: 10.1016/S0140-6736(12)60240-2.

  8. Chang A., Skirbekk V., Tyrovolas S. et al. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017. Lancet Public Health 2019; 4: e159–67. doi: 10.1016/S2468-2667(19)30019-2.

  9. Baron-Franco B., McLean G., Mair F.S. et al. Comorbidity and polypharmacy in chronic heart failure: a large cross-sectional study in primary care. Br J Gen Pract. 2017; 67(658): e314–e320. doi: 10.3399/bjgp17X690533.

  10. Gerber Y., Weston S.A., Redfield M.M. et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015; 175(6): 996–1004. doi: 10.1001/jamainternmed.2015.0924.

  11. Senni M., Tribouilloy C.M., Rodeheffer R.J. et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998; 98(21): 2282–89. doi: 10.1161/01.cir.98.21.2282.

  12. Heidenreich P.A., Albert N.M., Allen L.A. et al.; American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013; 6: 606–19. doi: 10.1161/HHF.0b013e318291329a.

  13. Tsao C.W., Lyass A., Enserro D. et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 2018; 6: 678–85. doi: 10.1016/j.jchf.2018.03.006.

  14. Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013; 62(4): 263–71. doi: 10.1016/j.jacc.2013.02.092.

  15. Pfeffer M.A., Shah A.M., Borlaug B.A. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019; 124(11): 1598–617. doi:10.1161/CIRCRESAHA.119.313572.

  16. Lam C.S., Donal E., Kraigher-Krainer E., Vasan R.S. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011; 13(1): 18–28. doi: 10.1093/eurjhf/hfq121.

  17. McMurray J.J., Packer M., Desai A.S. et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004. doi: 10.1056/NEJMoa1409077.

  18. Ponikowski P., Voors A.A., Anker S.D. et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–200. doi: 10.1093/eurheartj/ehw128.

  19. Dargad R.R., Prajapati M.R., Dargad R.R., Parekh J.D. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor. Indian Heart J. 2018; 70 Suppl 1(Suppl 1): S102–S110. doi: 10.1016/j.ihj.2018.01.002.

  20. Packer M., McMurray J.J., Desai A.S. et al.; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015; 131(1): 54–61. doi: 10.1161/CIRCULATIONAHA.114.013748.

  21. Bayes-Genis A., Barallat J., Galan A. et al. Multimarker strategy for heart failure prognostication. value of neurohormonal biomarkers: neprilysin vs NT-proBNP. Rev Esp Cardiol (Engl Ed). 2015; 68(12): 1075–84. doi: 10.1016/j.rec.2015.07.001.

  22. Packer M., Califf R.M., Konstam M.A. et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002; 106(8): 920–26. doi: 10.1161/01.cir.0000029801.86489.50.

  23. Kostis J.B., Packer M., Black H.R. et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004; 17(2): 103–11. doi: 10.1016/j.amjhyper.2003.09.014.

  24. Velazquez E.J., Morrow D.A., DeVore A.D. et al; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380(6): 539–48. doi: 10.1056/NEJMoa1812851.

  25. Lopez-Azor J.C., Vicent L., Valero-Masa M.J. et al. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort. ESC Heart Fail. 2019; 6(6): 1161–66. doi: 10.1002/ehf2.12527.

  26. Jering K.S., Claggett B., Pfeffer M.A. et al. Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and baseline characteristics. Eur J Heart Fail. 2021. doi: 10.1002/ejhf.2191. Online ahead of print.

  27. Moliner-Abos C., Mojon Alvarez D., Rivas-Lasarte M. et al. A Simple score to identify super-responders to sacubitril/valsartan in ambulatory patients with heart failure. Front Physiol. 2021; 12: 642117. doi: 10.3389/fphys.2021.642117.

  28. Российское кардиологическое общество (РКО). Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11): 311–374. [Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 25(11): 311–374 (In Russ.)]. doi: https://doi.org/10.15829/1560-4071-2020-4083.

  29. Elgendy I.Y., Mahtta D., Pepine C.J. Medical Therapy for heart failure caused by ischemic heart disease. Circ Res. 2019; 124(11): 1520–35. doi: 10.1161/CIRCRESAHA.118.313568.

  30. Solomon S.D., Zile M., Pieske B. et al.; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012; 380(9851): 1387–95. doi: 10.1016/S0140-6736(12)61227-6.

  31. Solomon S.D., McMurray J.J.V., Annand I.S. et al. for the PARAGON-HF Investigators and Committee. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381(17): 1609–20. doi: 10.1056/NEJMoa1908655.

  32. Jering K.S., Zannad F., Claggett B. et al. Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF. JACC Heart Fail. 2021; 9(1): 13–24. doi: 10.1016/j.jchf.2020.08.014

  33. Hsieh H.L., Chen C.Y., Chen C.H. et al. Renal protective effect of sacubitril/valsartan in patients with heart failure. Sci Rep. 2021; 11(1): 4593. doi: 10.1038/s41598-021-84118-8.

  34. Shah S., Wachter R, Solomon S. et al. Angiotensin receptor neprilysin inhibition compared with individualized medical therapy for comorbidities in patients with heart failure and preserved ejection fraction – the PARALLAX trial. ESC Virtual Congress 2020.

  35. Pieske B. Angiotensin receptor-neprilysin inhibition compared with individualized medical therapy for comorbidities in patients with heart failure and preserved ejection fraction: the PARALLAX trial. Presented at: ESC 2020. August 30, 2020. Available at: https://www.acc.org/latest-in-cardiology/clinical-trials/2020/08/28/17/06/parallax (date of access – 04.05.2021).

  36. Vicent L., Ayesta A., Esteban-Fernandez A. et al. Sex influence on the efficacy and safety of sacubitril/valsartan. Cardiology. 2019; 142(2): 73–78. doi: 10.1159/000498984

  37. Solomon S.D., Vaduganathan M., Claggett B.L et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020; 141(5): 352–61. doi: 10.1161/CIRCULATIONAHA.119.044586.


About the Autors

Vera N. Larina, MD, professor, head of the Department of polyclinic therapy of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117437, Moscow, 1 Ostrovityaninova Str. Tel.: +7 (910) 473-35-66. E-mail: larinav@mail.ru. ORCID: 0000-0001-7825-5597


Similar Articles

Back to Content

Бионика Медиа